Genelux Reports Promising Early Results for Olvi-Vec in Advanced Lung Cancer Trials
核心洞察
Olvi-Vec demonstrated a 33% overall response rate in platinum-relapsed small cell lung cancer patients, with two of three partial responses occurring in the highest dose cohort showing tumor shrinkage of approximately 55% and 85%.
In non-small cell lung cancer patients, the therapy achieved a 60% disease control rate with tumor reductions up to 22.7% compared to baseline measurements.
The oncolytic immunotherapy was generally well tolerated across both trials and showed potential for durable responses, with one patient achieving 12.1 months of progression-free survival.
Genelux Corporation announced encouraging interim results from two ongoing clinical trials evaluating Olvi-Vec, an investigational oncolytic immunotherapy, in patients with advanced lung cancer whose disease progressed after standard platinum-based treatment. The data, released on January 5, 2026, demonstrate promising anti-tumor activity and tolerability across both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) patient populations.
Strong Response Rates in Small Cell Lung Cancer
In the Phase 1b/2 SCLC trial, Olvi-Vec showed notable efficacy in patients with platinum-relapsed or platinum-refractory disease. As of the December 23, 2025 data cutoff, nine patients were evaluable for response, with three achieving partial responses for an overall response rate of 33%.
The most striking results emerged from the highest dose cohort tested, where two of three patients experienced partial responses with tumor shrinkage of approximately 55% and 85% from baseline. This represents a 67% overall response rate in the highest dose group, potentially suggesting a dose-response relationship.
Overall, six of the nine patients achieved disease control, meaning their cancer either shrank or remained stable, resulting in a disease control rate of 67%. All six patients who achieved disease control experienced reductions in their target lesions compared with baseline measurements, with tumor shrinkage ranging from 24% to 85%.
Durability Signals and Treatment Benefits
Early signs suggest some responses may be durable. One patient with one prior line of therapy achieved an ongoing progression-free survival of 12.1 months at the time of the most recent scan. Another patient who had received four prior lines of treatment experienced progression-free survival of 7.7 months, compared with 1.9 months on the patient's most recent previous therapy—an improvement of 5.8 months.
"We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to demonstrate promising anti-tumor activity and tolerability in patients with relapsed or refractory lung cancers," said Thomas Zindrick, president, CEO, and chairman of Genelux.
Non-Small Cell Lung Cancer Results
The Phase 2 VIRO-25 study in advanced or metastatic recurrent NSCLC also showed early anti-tumor activity. As of the December 31, 2025 data cutoff, five patients were evaluable for response, with three achieving disease control for a disease control rate of 60%.
Tumor size changes among the three patients who achieved disease control were 8.9%, -18.9%, and -22.7% respectively, compared to baseline, with the latter two representing meaningful tumor reductions of nearly 19% and 23%.
Trial Design and Safety Profile
The Phase 1b/2 SCLC trial is an open-label study evaluating a single intravenous cycle of Olvi-Vec given in multiple doses in combination with platinum and etoposide chemotherapy. The trial enrolls patients whose disease progressed after prior treatment with platinum and etoposide and is being conducted in China by Genelux's licensing partner, Newsoara HYK Biopharmaceuticals (搜索) Co., Ltd.
The Phase 2 VIRO-25 trial is enrolling patients with advanced or metastatic recurrent NSCLC in the United States. Participants previously received standard frontline treatment with platinum chemotherapy and an immune checkpoint inhibitor. In this study, Olvi-Vec is administered intravenously in combination with platinum chemotherapy and an immune checkpoint inhibitor.
Across both trials, Olvi-Vec was generally well tolerated, with no new safety concerns reported as of the respective data cutoff dates. Notably, patients who experienced tumor responses in the SCLC study did not receive maintenance immunotherapy following treatment, as the trial is primarily focused on safety and dose escalation.
Mechanism of Action and Future Development
Olvi-Vec is an oncolytic immunotherapy designed to kill cancer cells directly, stimulate an immune response, and modify the tumor microenvironment. Researchers are studying whether this approach can help make tumors sensitive again to platinum-based chemotherapy, which is commonly used to treat lung cancer but often stops working after disease progression.
The studies are designed to determine whether Olvi-Vec can be effectively delivered systemically, rather than locally, which could support its development across multiple solid tumor types. Both trials remain ongoing, with continued enrollment in dose-escalation cohorts aimed at optimizing efficacy, safety and tolerability.
"While these data remain preliminary, they reinforce our commitment to advancing two registration-path trials in progressive lung cancers, addressing a significant unmet medical need and building on our success in platinum-resistant/refractory ovarian cancer," Zindrick continued. "Looking ahead, 2026 will be a pivotal year with topline data from the Phase 3 registration trial in ovarian cancer expected in the second half and additional lung cancer trial readouts anticipated throughout the year."
Genelux expects to report additional interim lung cancer data throughout 2026, along with topline results from a Phase 3 trial evaluating Olvi-Vec in patients with platinum-resistant or platinum-refractory ovarian cancer.